The past year hasn't been kind to the stocks featured in this article.
Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling knives.
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer.
However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
Hitting a new 52-week low can be a pivotal moment for any stock.
These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
Hitting a new 52-week low can be a pivotal moment for any stock.
These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
Nintendo and Sony plan price hikes on game consoles due to US tariffs, with consumers potentially paying up to 30% more. Microsoft may have smoother sales.
A drop in oil prices may still provide relief at the gas pump, but as a signal of what’s happening across the broader economy, it’s a red flag we ignore at our peril.
STMicroelectronics plans to reshape its global manufacturing footprint, prioritizing investments in future-ready infrastructure, digital technologies, and complementary ecosystems.
Peter Lynch’s approach focused on identifying undervalued growth stocks with simple, scalable businesses. We examine whether UNITED THERAPEUTICS CORP (NASDAQ:UTHR) fits the characteristics of a Lynch-approved investment.
